Palbociclib plus endocrine therapy in HER2 negative, hormonal receptor-positive, advanced breast cancer: A real-world experience.
J Cell Physiol. 2019.
PMID: 30536609
Search Page
Save citations to file
Email citations
Send citations to clipboard
Add to Collections
Add to My Bibliography
Create a file for external citation management software
Your saved search
Your RSS Feed
Filters
Results by year
Table representation of search results timeline featuring number of search results per year.
| Year | Number of Results |
|---|---|
| 2018 | 1 |
| 2019 | 1 |
| 2020 | 1 |
| 2023 | 0 |
Search Results
2 results
Results by year
Citations
1
article
found by citation matching
Search results
Filters applied: . Clear all
Page 1
Palbociclib plus endocrine therapy in HER2 negative, hormonal receptor-positive, advanced breast cancer: A real-world experience.
Pizzuti L, Giordano A, Michelotti A, Mazzotta M, Natoli C, Gamucci T, De Angelis C, Landucci E, Diodati L, Iezzi L, Mentuccia L, Fabbri A, Barba M, Sanguineti G, Marchetti P, Tomao S, Mariani L, Paris I, Lorusso V, Vallarelli S, Cassano A, Aroldi F, Orlandi A, Moscetti L, Sergi D, Sarobba MG, Tonini G, Santini D, Sini V, Veltri E, Vaccaro A, Ferrari L, De Tursi M, Tinari N, Grassadonia A, Greco F, Botticelli A, La Verde N, Zamagni C, Rubino D, Cortesi E, Magri V, Pomati G, Scagnoli S, Capomolla E, Kayal R, Scinto AF, Corsi D, Cazzaniga M, Laudadio L, Forciniti S, Mancini M, Carbognin L, Seminara P, Barni S, Samaritani R, Roselli M, Portarena I, Russo A, Ficorella C, Cannita K, Carpano S, Pistelli M, Berardi R, De Maria R, Sperduti I, Ciliberto G, Vici P.
Pizzuti L, et al.
J Cell Physiol. 2019 Jun;234(6):7708-7717. doi: 10.1002/jcp.27832. Epub 2018 Dec 10.
J Cell Physiol. 2019.
PMID: 30536609
Data from 423 human epidermal growth factor receptor 2-negative (HER2-), hormone receptor-positive (HR+) advanced breast cancer (aBC) patients treated with palbociclib and endocrine therapy (ET) w …
Data from 423 human epidermal growth factor receptor 2-negative (HER2-), hormone receptor-positive …
Item in Clipboard
RENATA study-Latin American prospective experience: clinical outcome of patients treated with palbociclib in hormone receptor-positive metastatic breast cancer-real-world use.
Petracci F, Abuin GG, Pini A, Chacón M.
Petracci F, et al.
Ecancermedicalscience. 2020 Jun 17;14:1058. doi: 10.3332/ecancer.2020.1058. eCollection 2020.
Ecancermedicalscience. 2020.
PMID: 32582373
Free PMC article.
BACKGROUND: In hormone receptor-positive, HER-2 negative (HR+/HER2-) advanced breast cancer (ABC) endocrine therapy (ET) plus cyclin-dependent kinase 4/6 inhibitors (CDK4/6i) in first and second line imp …
BACKGROUND: In hormone receptor-positive, HER-2 negative (HR+/HER2-) advanced breast can …
Item in Clipboard
Cite
Cite